Sangamo Therapeutics (SGMO) Tops Q3 EPS by 10c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. CSCO
6. KTOS
7. JPM
8. DT
9. AON
10. TMUS

Go back to Sangamo Therapeutics (SGMO) Tops Q3 EPS by 10c, Revenues Beat

Sangamo Therapeutics (SGMO) Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at ASH

November 6, 2019 9:01 AM EST

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster presentations at the 61st Annual Meeting of the American Society of Hematology (ASH). The ASH abstracts, which were submitted on August 3, 2019, were released online this morning. The conference will take place in Orlando, FL, from December 7-10, 2019.

Gene Therapy

Abstract #2060: Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to... More